Axitinib CAS:319460-85-0

Axitinib CAS:319460-85-0 (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types. Axitinib CAS:319460-85-0 was approved for RCC by the U.S. Food and Drug Administration after showing a modest increase in progression-free survival, though there have been reports of fatal adverse effects. Axitinib CAS:319460-85-0 could be supplied in different size with competitive price.
Chat Now

Product Details

Name: Axitinib

Other name:

N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide

Benzamide, N-methyl-2-[[3-[(E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-


CAS:319460-85-0

EINECS:638-771-6

MF:C22H18N4OS

MW:386.47

Appearance:Off-white solid

MP:213-215℃

Purity:98%min

Package:50mg, 1g, 10g, bulk package

Applications: Organic intermediate;Pharmaceutical intermediate


Inquiry